(firstQuint)A Safety and Efficacy Study of Tralokinumab in Adults With Asthma.

 Interleukin-13 (IL-13) is a key mediator in the pathogenesis of established asthmatic disease.

 Tralokinumab is a human monoclonal antibody that blocks IL-13, which may result in improved control of asthma.

 This study will determine whether the addition of tralokinumab to standard asthma medications results in a reduced rate of asthma exacerbations in subjects with severe asthma.

.

 A Safety and Efficacy Study of Tralokinumab in Adults With Asthma@highlight

The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.

